ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation  by Qing, Guoliang et al.
Cancer Cell
ArticleATF4 RegulatesMYC-Mediated Neuroblastoma
Cell Death upon Glutamine Deprivation
Guoliang Qing,1,3,4,5 Bo Li,1,4 Annette Vu,2 Nicolas Skuli,1,3 Zandra E. Walton,1 Xueyuan Liu,2 Patrick A. Mayes,2
David R. Wise,1 Craig B. Thompson,1,6 John M. Maris,1,2 Michael D. Hogarty,2 and M. Celeste Simon1,3,*
1Abramson Family Cancer Research Institute
2Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Department of Pediatrics
Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA
3Howard Hughes Medical Institute, 421 Curie Boulevard, Philadelphia, PA 19104, USA
4These authors contributed equally to this work
5Present address: Provincial Key Laboratory of Drug Target Research and Pharmacodynamic Evaluation, Tongji Medical College,
Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan, Hubei Province 430030, China
6Present address: Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
*Correspondence: celeste2@mail.med.upenn.edu
http://dx.doi.org/10.1016/j.ccr.2012.09.021SUMMARYOncogenic Myc alters mitochondrial metabolism, making it dependent on exogenous glutamine (Gln) for cell
survival. Accordingly, Gln deprivation selectively induces apoptosis in MYC-overexpressing cells via
unknown mechanisms. Using MYCN-amplified neuroblastoma as a model, we identify PUMA, NOXA, and
TRB3 as executors of Gln-starved cells. Gln depletion inMYC-transformed cells induces apoptosis through
ATF4-dependent, but p53-independent,PUMA andNOXA induction.MYC-transformed cells depend on both
glutamate-oxaloacetate transaminase and glutamate dehydrogenase to maintain Gln homeostasis and
suppress apoptosis. Consequently, either ATF4 agonists or glutaminolysis inhibitors potently induce
apoptosis in vitro and inhibit tumor growth in vivo. These results reveal mechanisms whereby Myc sensitizes
cells to apoptosis, and validate ATF4 agonists and inhibitors of Gln metabolism as potential Myc-selective
cancer therapeutics.INTRODUCTION
Neuroblastoma is one of the most frequent solid tumors de-
tected in childhood, accounting for 10%–15% of all pediatric
oncology deaths (Maris, 2010). Risk factors indicative of poor
prognosis include age > 18 months at diagnosis, advanced
stage, unfavorable histologic grade, and MYCN amplification
(Maris, 2010). Recent studies demonstrated that mutations in
the anaplastic lymphoma kinase (ALK) gene are causal for
most familial neuroblastomas and occur in 10% of sporadic
neuroblastomas, and that polymorphisms in genes encoding
BRCA1-associated RING Domain-1 (BARD1) and LIM domain
only 1 (LMO1) influence disease susceptibility (Capasso et al.,Significance
Myc-transformed cells depend on elevated glutaminolysis for s
trigger apoptosis upon glutamine (Gln) withdrawal. Here we
expression of the proapoptotic proteins PUMA, NOXA, and TR
ing neuroblastoma cells. Moreover, xenograft and autochthono
molecules that either enhance ATF4 activity or block glutami
human neuroblastomas selectively overexpress high-affinity G
late with poor prognosis. These data suggest that drugs that inh
therapeutic strategies for treating theR40% of human cance
Can2009; Mosse´ et al., 2008; Wang et al., 2011). Nevertheless,
MYCN amplification remains the most important oncogenic
driver and reliable prognostic factor, and is highly correlated
with advanced disease stage and a poor survival rate. MYCN
amplification occurs in 20%–25% of neuroblastomas overall
and 40% of high-risk cases (Maris, 2010). Alternatively, elevated
c-MYC expression correlates with poor prognosis in MYCN-
nonamplified neuroblastoma (Liu et al., 2008). High levels of
Myc activity likely contribute to aggressive phenotypes by regu-
lating and/or cooperating with other oncogenic pathways.
Neuroblastomas, like other solid tumors, require specific
metabolic alterations to fuel their deregulated growth and inva-
sion into surrounding tissues. The regulation and dynamics ofurvival, but little is known about themolecular pathways that
describe a regulatory mechanism whereby ATF4 induces
B3 to promote apoptosis in Gln-deprived, Myc-overexpress-
us murine neuroblastoma tumor growth is inhibited by small
nolysis. Importantly, we demonstrate that MYCN-amplified
ln transporters and other glutaminolytic enzymes that corre-
ibit glutaminolysis or elevate ATF4 functionmay be effective
rs that overexpress Myc.
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ATF4 Regulates MYC-Mediated Cell Deaththe central metabolic pathways and energy production differ
between normal and malignant cells. Fast-growing, poorly
differentiated tumor cells typically exhibit increased aerobic
glycolysis, a phenomenon known as the Warburg effect (Vander
Heiden et al., 2009). Cancer cells also depend on sustained
mitochondrial activity, and provide biosynthetic substrates to
support enhanced proliferation and survival. Glucose and gluta-
mine (Gln) are two of the most abundant nutrients consumed
by neoplastic cells (DeBerardinis et al., 2008). In most human
cancers, >80% of the absorbed glucose is catabolized into
lactate. While glycolytic ATP generation maintains the cellular
bioenergetics, the remaining glucose enters the tricarboxylic
acid cycle (TCA) cycle, where it is converted to citrate. Citrate
is then preferentially exported into the cytosol to support lipid
synthesis. However, increased citrate efflux from mitochondria
can deplete TCA cycle metabolites. To prevent this, Gln (another
major substrate oxidized by tumor cells) replenishes a truncated
TCA cycle through a process termed anaplerosis (DeBerardinis
et al., 2008). Moreover, Gln metabolism maintains mitochondrial
integrity and nicotinamide adenine dinucleotide phosphate
(NADPH) levels needed for redox homeostasis and macro-
molecular synthesis (DeBerardinis et al., 2008; Metallo et al.,
2012; Mullen et al., 2012; Wise et al., 2011).
MYC oncogenes regulate multiple aspects of tumor metabo-
lism, enabling cancer cells to avidly uptake both glucose and
Gln (Dang, 2012). The MYC family consists of three members:
c-MYC, MYCN, and MYCL. Whereas c-MYC is broadly deregu-
lated in many human tumors, MYCN expression is more
restricted to neural tumors and MYCL is predominantly found
in small cell lung cancer. Both c-Myc and N-Myc have been
documented to enhance aerobic glycolysis by directly acti-
vating the transcription of glycolytic genes (Dang, 2012; Qing
et al., 2010). Oncogenic c-Myc has been linked to increased
glutaminolysis through coordinated transcriptional and post-
transcriptional programs (Gao et al., 2009; Wise et al., 2008).
For instance, c-Myc directly activates the transcription of
SLC1A5 (solute carrier family 1, member 5, also known as
ASCT2) and SLC38A5 (solute carrier family 38, member 5,
also known as SN2), which encode two highly efficient Gln
transporters (Wise et al., 2008). Furthermore, c-Myc indirectly
stimulates glutaminase (encoded by GLS) expression through
suppression of microRNAs miR-23a/b, which specifically target
the GLS 30 untranslated region and inhibit GLS messenger RNA
(mRNA) translation (Gao et al., 2009). Thus, c-Myc coordinates
the expression of multiple genes that are necessary for Gln
metabolism, replenishing the TCA cycle and supplying essential
intermediates for nucleic acid, amino acid, and glutathione
biosynthesis.
MYCN amplification is strongly correlated with advanced-
stage neuroblastoma (Maris, 2010) and is used worldwide for
patient-risk classification. MYCN-amplified neuroblastomas
are frequently resistant to conventional therapeutic drugs, due
in part to defects in death-inducing signaling complex (DISC)
components such as Caspase 8 (encoded by CASP8; Teitz
et al., 2000) and altered ABC transporter expression (Porro
et al., 2010). Therefore, it is critical to identify effective druggable
targets in neuroblastoma. By achieving systemic inhibition in
a Ras-mediated lung adenocarcinoma mouse model, Soucek
et al. (2008) demonstrated the benefit of targeting MYC632 Cancer Cell 22, 631–644, November 13, 2012 ª2012 Elsevier Inc(a recipient of multiple oncogenic signals) as an efficient and
tumor-specific cancer therapy. Thus far, however, no small
molecules targeting nonkinase oncoproteins such as MYC
have been developed. MYCN-amplified neuroblastomas are
highly vascular (Maris, 2010), which makes the use of antiangio-
genic agents (e.g., agents that target vascular endothelial
growth factor) a promising therapeutic approach. However,
recent studies demonstrated that antiangiogenics significantly
increase invasion and metastasis in multiple tumor models
(Ebos et al., 2009; Pa`ez-Ribes et al., 2009), which has somewhat
decreased enthusiasm for this treatment in cancers such as
neuroblastoma.
Myc-mediated metabolic reprogramming triggers cellular
dependency on exogenous Gln to sustain viability. Conse-
quently, Gln depletion kills transformed cells in a Myc-depen-
dent manner (Le et al., 2012; Wise et al., 2008; Yuneva et al.,
2007). However, whether genes involved in Gln metabolism are
deregulated in primary human tumors, and the mechanisms
responsible for Gln deprivation-mediated cell death remain
largely unknown. We therefore sought to determine whether
these cell-death pathway(s) and/or alterations of Glnmetabolism
can be therapeutically exploited.
RESULTS
Gln Depletion Induces Neuroblastoma Cell Death
in an N-Myc Dependent Manner
To evaluate the impact ofMYC on cell death uponGln starvation,
we analyzed human tumor cell lines overexpressing N-Myc
(Kelly, from MYCN-amplified neuroblastoma) or c-Myc (SF188,
from glioma). SHEP cells (from MYCN nonamplified neuroblas-
toma) with low N- or c-Myc levels were used for comparison
(Figure 1A). We then subjected these cells to Gln deprivation
for 48 hr. As expected, Gln starvation induced significant cell
death in Kelly and SF188 cells associated with Myc overex-
pression (Figures 1B and 1C), whereas SHEP cells exhibited
minimal cell death under similar conditions (Figures 1B and
1C). Furthermore, direct N-Myc inhibition by specific small
interfering RNAs (siRNAs) in Kelly cells alleviated cell death
upon Gln loss (Figures S1A and S1B available online), confirming
the essential role of Myc in this process. When tested in cultured
cell lines, elevated c-Myc was shown to enhance the transcrip-
tion of genes involved in glutaminolysis (Wise et al., 2008).
However, whether this in vitro observation is representative of
what occurs in human tumors remained unknown. To address
this issue, we evaluated 80 primary neuroblastomas of diverse
risk classes with and without MYCN amplification. Of note,
ASCT2, LAT1 (or SLC7A5, solute carrier family 7, member 5),
LAT2 (or SLC7A6, solute carrier family 7, member 6), GLS2
(glutaminase 2), GOT2 (glutamate-oxaloacetate transaminase
2), and SLC1A7 (solute carrier family 1 glutamate transporter,
member 7) mRNAs were significantly elevated in MYCN-ampli-
fied tumors when compared with nonamplified tumors (Figures
1D and S1C; data not shown). In contrast, GLS (also known as
GLS1, glutaminase 1), GLUD1 (glutamate dehydrogenase), and
SN1 (solute carrier family 38, member 3) expression was largely
unchanged or even reduced (Figure S1C; data not shown),
suggesting that they are not N-Myc targets. Taken together,
these results suggest that ASCT2, LAT1, LAT2, GLS2, GOT2,.
Figure 1. Gln Starvation Triggers Tumor Cell Death in a MYC-Dependent Manner
(A) Western blot analysis of Myc (N-Myc and c-Myc) expression in Kelly, SF188, and SHEP cells. b-actin was used as a loading control.
(B) Representative images of Kelly, SF188, and SHEP cells in the presence or absence of Gln for 48 hr. Scale bars represent 50 mm.
(C) Quantification of cell death by PI-Annexin V staining. Data are presented as an average of triplicates. Error bars represent the standard deviation (SD).
*p < 0.001.
(D) Relative expression of MYCN, ASCT2, LAT1, and GLS2 in primary neuroblastoma tumors. 1, Low-risk group (28 tumors); 2, MYCN-nonamplified, high-risk
group (32 tumors); and 3,MYCN-amplified, high-risk group (20 tumors); defined according to International Neuroblastoma Risk Group criteria (Maris, 2010). Data
are presented as box plots; the box represents the 25th through 75th percentiles (the line through the box denotes themedian), and the whiskers above and below
extend to the 90th and 10th percentiles, respectively.
See also Figure S1.
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lism in MYCN-amplified neuroblastomas.
Gln Depletion Induces Tumor Cell Death Depending
Largely on Bax and Caspase Activities
Studies using gene-targeted mice revealed that cellular apo-
ptosis is frequently governed by two proapoptotic Bcl-2 family
proteins: Bax and Bak (Wei et al., 2001). Bax and Bak exert
similar function in most stress-induced apoptotic pathways
and can functionally substitute for each other. To determine
whether Gln deprivation induces apoptosis via Bax and/or Bak,
we first examined Bax and Bak activation in Kelly cells using
conformation-specific antibodies. Gln starvation activated both
Bax and, to a lesser extent, Bak, as the 6A7 antibody for Bax
and Ab1 antibody for Bak efficiently immunoprecipitated these
proteins in comparison with nonstarved cells (Figure 2A). Sub-
sequently, Bax and Bak were each depleted by two distinct
siRNAs (Figure 2B) and the cells were subjected to Gln starva-
tion. Surprisingly, inhibition of Bax, but not Bak, significantly
decreased the death of N-Myc-overexpressing Kelly cells upon
Gln deprivation (Figure 2C). This was recapitulated in c-Myc-
overexpressing SF188 cells (Figure 2D), suggesting a general
mechanism that depends predominantly on Bax for Myc-
mediated cell death during Gln limitation. Of note, previous
data demonstrated that Bax depletion cooperates with c-Myc
during murine lymphomagenesis (Eischen et al., 2001). Because
Bax activates downstream caspase-dependent and/or -inde-
pendent pathways, we treated Kelly cells with escalating doses
of z-VAD-fmk (z-VAD), a broad-spectrum caspase inhibitor, andCanfound that 50 mM of z-VAD completely inhibited Caspase 3
activation and Kelly cell death (data not shown). Therefore,
a caspase-dependent pathway regulates Myc-mediated cell
death during Gln starvation. Consistent with this finding, block-
ing Bax mitochondrial translocation using the cell membrane-
permeable V5 peptide inhibitor (Sawada et al., 2007; Figure 2E)
partially rescued Gln deprivation-induced cell death (Figure 2F).
Therefore, MYCN-amplified neuroblastomas provide an attrac-
tive model for studying the molecular mechanisms that underlie
the connection between Myc overexpression and Gln addiction.
PUMA, NOXA, and TRB3 Promote Gln
Deprivation-Mediated Cell Death
Unlike Bak, Bax can be sequestered in the cytosol by specific
interaction with the non-Bcl2 family protein Ku70 in an acetyla-
tion-dependent fashion (Figure S2A). Cellular stress causes
Ku70 acetylation by CBP and PCAF, leading to subsequent
Bax dissociation, Bax activation, and apoptosis (Sawada et al.,
2007). We examined whether Gln deprivation affects Ku70
acetylation and Bax association. Kelly cell starvation did not
result in detectable changes in either Ku70 acetylation or
Ku70-Bax interaction, whereas treatment with the broad deace-
tylase inhibitor TSA increased Ku70 acetylation and disrupted
Ku70-Bax binding (Figure S2B). Therefore, we concluded that
Ku70 is not involved in Bax activation upon Gln withdrawal.
We then investigated expression of multiple factors inducing
apoptosis upstream of Bax, and observed in Gln-starved Kelly
cells a significant increase in PUMA, NOXA, and TRB3 (tribbles
homolog 3) mRNA (Figure 3A) and protein (Figure 3B). TRB3 iscer Cell 22, 631–644, November 13, 2012 ª2012 Elsevier Inc. 633
Figure 2. Gln Depletion Triggers Bax-Dependent but Bak-Independent Cell Death
(A) Immunoprecipitation of active Bax and Bak using conformation-specific antibodies in Kelly cells subjected to Gln starvation at indicated time points.
(B) Protein levels of Bax and Bak upon siRNA knockdown in Kelly cells. Bar graphs show the quantification results. *p < 0.001.
(C and D) Viability of Kelly cells (C) and SF188 cells (D) upon indicated siRNA knockdown were examined by PI-Annexin V staining after 48 hr of Gln starvation.
Data are shown as an average of triplicates.
(E) Immunoblotting of Bax in the cytosolic (Cyto) and mitochondrial (Mito) fraction of NLF cells treated with V5 peptide in the presence or absence of Gln. VDAC
and actin antibodies were used as controls for mitochondrial and cytosolic protein purification.
(F) Gln-starvation-induced cell death with or without V5 peptide treatment was examined by PI-Annexin V staining. Shown are average results from three
experiments.
All error bars represent SD.
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a pseudo-kinase protein that is frequently induced by endo-
plasmic reticulum (ER) stress (Ohoka et al., 2005). Of note,
TRB3 is activated by the ATF4/CHOP pathway and in turn
represses CHOP, possibly via direct CHOP interaction, blocking
CHOP coactivator recruitment. Depletion of PUMA alone by
specific siRNAs significantly inhibited Myc-mediated Kelly cell
death upon Gln deprivation, and a triple depletion of PUMA,
NOXA, and TRB3 further reduced apoptosis (Figure 3C). We
then extended our study to a number of additional neuroblas-
toma cell lines. A total of 17 neuroblastoma lines, including
nine MYCN-amplified and eight MYCN-nonamplified lines were
subjected to Gln starvation. Of note, six of nineMYCN-amplified
lines, but only one MYCN-nonamplified line exhibited Gln
dependence (Figure 3D and data not shown). The single outlier
for Gln dependence absent MYCN amplification was NBL-S,
a cell line with markedly deregulated N-Myc activity through
protein stabilization (Liu et al., 2008). We examined N-Myc
expression in two MYCN-amplified lines (NLF and IMR32) and
NBL-S, and corroborated similar levels of deregulated protein
(Figure S2C; Qing et al., 2010), underscoring the association
between deregulated MYCN and Gln dependence. Moreover,
significant PUMA, NOXA, and TRB3 induction was observed
in all three cell lines when Gln was absent (Figure S2D), and
a combined inhibition of PUMA, NOXA, and TRB3 reversed634 Cancer Cell 22, 631–644, November 13, 2012 ª2012 Elsevier IncIMR32 and NLF cell death upon Gln removal (Figure 3E). Efficient
siRNA-mediated depletion of PUMA, NOXA, and TRB3 protein
in both Kelly and NLF cells was confirmed by western blot (Fig-
ure 3F). Taken together, these results demonstrate that PUMA,
NOXA, and TRB3 work in concert to regulate Gln-deprivation-
mediated cell death in MYCN-amplified neuroblastomas.
PUMA, NOXA, and TRB3 Are Regulated by
a p53-Independent, ATF4-Dependent Mechanism
PUMA potently induces apoptosis, and its overexpression is
sufficient to cause cell death in numerous cell types because
it directly binds and antagonizes many antiapoptotic Bcl2
family members, resulting in mitochondrial dysfunction and
Bax activation (Letai et al., 2002). PUMA is normally expressed
at low levels but is rapidly induced by p53 and other factors
(Yu and Zhang, 2008). Because Gln loss in Kelly cells specifically
activates PUMA and NOXA (both well-known p53 targets), we
inhibited p53 by siRNA (Figure 4A) in Kelly cells and then sub-
jected the cells to Gln starvation. Interestingly, p53 inhibition
had no effect on PUMA, NOXA, and TRB3 induction (Figure 4B),
whereas the expression of another p53 target, TIGAR (p53-
induced glycolysis and apoptosis regulator; Bensaad et al.,
2006), was significantly inhibited under the same conditions
(Figure 4B). In addition to p53, other transcription factors have
been implicated in context-dependent PUMA and/or NOXA.
Figure 3. PUMA, NOXA, and TRB3, but Not Ku70, Are Involved in Gln-Deprivation-Mediated Cell Death
(A) RT-PCR analysis of genes involved in apoptosis. Data are shown as an average of triplicates.
(B) Western blot analysis of indicated protein levels in Gln-starved Kelly cells.
(C) The viability of Kelly cells transfectedwith the indicated siRNAs in the presence or absence of Gln was analyzed by AnnexinV-PI staining. Data are shown as an
average of triplicates.
(D) Examination of Gln-starvation-induced cell death in five MYCN-amplified and four MYCN-nonamplified neuroblastoma cell lines. Cell death was measured
by Annexin V-PI staining.
(E) The viability of IMR32 and NLF cells transfected with siRNAs targeting PUMA, NOXA, and TRB3 in the presence or absence of Gln was analyzed by
AnnexinV-PI staining. Data are shown as an average of triplicates.
(F) Western blots confirming the effect of siRNA knockdown.
All error bars represent the SD; *p < 0.01, **p < 0.005. See also Figure S2.
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was inhibited by specific siRNAs without a detectable effect on
PUMA and NOXA activation (data not shown).
To identify PUMA regulatory factor(s), we performed bio-
informatic analyses, and identified a conserved ATF4-binding
site within the PUMA promoter region (Figure S3A). ATF4 knock-
down (Figure 4C) potently inhibited PUMA, NOXA, and TRB3
activation in Gln-starved Kelly, IMR32, and NLF neuroblastoma
cells (Figures 4D and S3B). A chromatin immunoprecipitation
(ChIP) analysis demonstrated that significant ATF4 pools were
recruited to the PUMA promoter along with enhanced RNA
polymerase II (Pol II) occupancy in Gln-starved Kelly cells (Fig-
ure 4E). We created a luciferase reporter construct using
a pGL3 plasmid containing the putative ATF4-binding site (in
triplicate) 50 of the SV40 promoter (ATF4-RE/luc; Figure 4F). As
a control, we generated an additional construct harboring muta-
tions in the ATF4-binding motif (ATF4-REmut/luc; Figure 4F).
Compared with empty pGL3 vector and ATF4-REmut/luc,
ATF4-RE luciferase activity was significantly increased by
exogenous ATF4 or Gln starvation (Figure 4G). Interestingly,
we identified a different ATF4 response element within the
NOXA promoter (Figure S3C). Both ChIP and luciferase assays
confirmed that ATF4 directly activated NOXA transcriptionCanthrough binding to this site (Figures S3D–S3F). Furthermore,
two distinct ATF4 siRNAs significantly reduced Gln starvation-
induced death in Kelly and NLF cells (Figures 4H and 4I), which
was further alleviated by combinatorial inhibition of PUMA,
NOXA, and TRB3 (Figures 4I and 4J). To control for off-target
effects, independent siRNAs for PUMA, NOXA, and TRB3 were
used in these assays (compare Figures 4I and 4J with Figures
3C, 3E, and 3F). In contrast, ATF4 depletion in SF188 glioma
cells had little effect on Gln-starvation-induced cell death
(Figures S3G and S3H), possibly due to a different tumorigenic
background. A recent study indicated that ATF4 directly acti-
vates CHOP expression, which subsequently stimulates PUMA
and apoptosis (Galehdar et al., 2010). However, CHOP inhibition
in Gln-starved Kelly cells failed to affect PUMA and NOXA
activation (Figure S3I) or concomitant cell death (Figure S3J),
suggesting that CHOP was not involved in this process. Taken
together, these results indicate that ATF4 functions as a tran-
scription factor in directly regulating PUMA, NOXA, and TRB3
expression in MYCN-transformed cells.
Gln can be converted by two deamination reactions into
a-ketoglutarate (a-KG) to replenish a functional TCA cycle (Fig-
ure 4K). Because the TCA cycle provides a ‘‘hub’’ for multiple
metabolic pathways, loss of cycle intermediates could havecer Cell 22, 631–644, November 13, 2012 ª2012 Elsevier Inc. 635
Figure 4. ATF4, but Not p53, Is Responsible for PUMA, NOXA, and TRB3 Activation
(A) Protein levels of p53 with or without siRNA knockdown.
(B) The mRNA expression of indicated genes was examined by RT-PCR in Kelly cells transfected with a control siRNA or p53 siRNA in the presence or absence
of Gln. Data are shown as an average of triplicates.
(C) Protein levels of ATF4 in Kelly cells with or without siRNA knockdown.
(D) The indicated gene expression was quantitated by RT-PCR in Kelly cells transfected with a control or ATF4 siRNA in the presence or absence of Gln. Data are
shown as an average of triplicates.
(E) Specific chromatin binding of ATF4 evaluated by ChIP assay. Recruitment of Pol II was also assessed.
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ATF4 Regulates MYC-Mediated Cell Deathvarious consequences, including cell death (DeBerardinis et al.,
2008). Indeed, oxaloacetate (OAA), a cell-membrane-permeable
TCA-cycle intermediate, or dimethyl a-KG, a cell-membrane-
permeable a-KG analog, prevented apoptosis of Gln-starved
cells (Figure 4L). We reasoned that if ATF4-mediated PUMA
stimulation is critical for cell death, then OAA or a-KG should
decrease PUMA and NOXA expression when Gln is absent. As
expected, supplementation of OAA or a-KG (4 mM) efficiently
inhibited PUMA and NOXA induction (Figure 4M). Of note,
inhibition of both PUMA and NOXA correlated with that of
ATF4 (Figure 4M), raising the possibility that enhanced ATF4
transcription occurs following Gln withdrawal. Moreover, Kelly
cell treatment with actinomycin D, which abrogates ATF4 tran-
scriptional induction, significantly reduced ATF4 protein levels
when Gln was absent (Figure S3K). ATF4 transcriptional control
is largely unknown, except for stress-regulated transcription
factor p8, which induces ATF4 during cannabinoid-mediated
apoptosis (Carracedo et al., 2006). Although p8 expression
was significantly increased at both the mRNA and protein levels
in Gln-starved cells, p8 inhibition had no detectable effect on
ATF4 (Figure S3L). Because ATF4 is activated by Gln starvation,
we investigated whether ATF4 is regulated by signaling path-
ways that promote Gln metabolism, such as AMPK-mTOR
(Nicklin et al., 2009) and Myc (Gao et al., 2009; Wise et al.,
2008; Yuneva et al., 2007). However, siRNA knockdown of
AMPKa1 and a2 catalytic subunits or N-Myc had no significant
impact on ATF4 mRNA levels (Figure S3M). Finally, a bio-
informatic analysis of ATF4 regulatory regions identified ten
potential transcription factors involved in ATF4 induction.
However, their RNAi-mediated inhibition failed to decrease
ATF4 induction in Gln-starved cells (data not shown), suggesting
that other unidentified factor(s) are involved in this process.
ATF4 Translation Depends on the GCN2 Kinase,
but Not PERK, in the Absence of Gln
Translation of ATF4 mRNA is also regulated by stress signals
(Kilberg et al., 2009), transduced by multiple eIF2a kinases,
including GCN2 (general control nonrepressed-2), PERK (protein
kinase-like ER kinase), and PKR (double-strand RNA activated
protein kinase). Amino acid deprivation (usually essential ones
like leucine and lysine) triggers the amino acid response (AAR)
signal transduction pathway via GCN2, while ER disruption
and viral infection activate PERK and PKR, respectively. Mecha-
nistically, these kinases promote eIF2a phosphorylation at Ser
51. Phospho-eIF2a then binds eIF2B in a nonfunctional complex(F) Schematic representation of the consensus ATF4-binding site, the ATF4
(ATF4-REmut).
(G) Luciferase assay was performed using control, ATF4-RE, and ATF4-REmut co
shown as an average of triplicates.
(H) Viability of Kelly cells transfected with a control or ATF4 siRNA in the presence o
average of triplicates.
(I) Evaluation of Kelly and NLF cell death upon siRNA knockdown of ATF4 (using
TRB3 in the absence of Gln.
(J) Western blots confirming the effect of siRNA knockdown in (I).
(K) Diagram depicting Gln metabolism in the TCA cycle. See text for more detail
(L) Evaluation of Gln-starved Kelly cell death upon the addition of OAA or a-KG.
(M) RT-PCR analysis of the indicated genes in Kelly cells cultured in Gln-free or -r
shown as an average of triplicates.
All error bars represent SD; *p < 0.01, **p < 0.005. See also Figure S3.
Canthat suppresses global protein synthesis, while promoting
increased translation of select mRNAs, including ATF4 (Fig-
ure 5A). We first examined eIF2a phosphorylation in Kelly cells
at different time points. As expected, Gln starvation gradually
elevated eIF2a phosphorylation concomitantly with a dramatic
increase in total ATF4 protein (Figure 5B), suggesting that
ATF4 translation is also enhanced in Gln-starved Kelly cells. Of
note, this stress response is tightly linked to MYC overexpres-
sion. Although ATF4, PUMA, NOXA, and TRB3 transcripts
were somewhat increased in three MYCN-nonamplified cell
lines (SHEP, SKNAS, andEBC1) uponGln depletion (Figure S4A),
their protein levels did not change in all cell lines tested
(Figure S4B). Consistent with this result, MYCN-nonamplified
neuroblastoma cells failed to engage the eIF2a-ATF4 pathway,
as shown by similar levels of p-eIF2a in both conditions
(Figure S4B).
One highly conserved function ofMYC family members across
species is to activate ribosome biogenesis and mRNA trans-
lation, which are essential for cell growth (Dang, 2012). Gln is
utilized in O-linked b-N-acetylglucosamine (O-GlcNAc) modifi-
cation of nascent polypeptides, a posttranslational modification
that is critical for transcription factor function (Butkinaree et al.,
2010). Theoretically, Gln deprivation results in protein misfolding
and ER accumulation, leading to ER stress pathway activation. In
addition, oncogenic Myc converts the nonessential amino acid
Gln into an essential one, triggering cellular addiction to Gln
(Wise et al., 2008; Yuneva et al., 2007) and AAR stress pathway
activation. Indeed, the mRNA levels of ER stress-inducing genes
ASNS (asparagine synthetase), GRP78 (glucose-regulated
protein 78), and XBP-1 (X-box binding protein 1) were signifi-
cantly increased in Gln-starved Kelly cells (data not shown).
Whereas glucose starvation in mouse embryonic fibroblasts
(MEFs) induces ATF4 translation via both GCN2 and PERK,
Gln depletion affects ATF4 levels in a GCN2-dependent but
PERK-independent manner (Ye et al., 2010). To confirm this
result, we examined wild-type (WT), Gcn2/, and Perk/
MEFs. Indeed, lack of GCN2, but not PERK, abolished ATF4
translation in response to Gln depletion, as increased ATF4
abundance was selectively lost in Gcn2/ but not Perk/
cells (Figure 5C). In parallel, eIF2a phosphorylation was ex-
clusively abrogated in Gcn2/ fibroblasts (Figure 5C). We
then depleted GCN2 and PERK in Kelly cells (Figure 5D), and
demonstrated that GCN2 inhibition selectively abrogated
eIF2a phosphorylation in association with decreased ATF4
translation (Figure 5E).response element (ATF4-RE) within the PUMA promoter and its mutant
nstructs with or without exogenous ATF4 expression or Gln starvation. Data are
r absence of Glnwas examined by PI-Annexin V staining. Data are shown as an
independent siRNAs from [C] and [H]), or a combination of PUMA, NOXA, and
s.
eplete medium, or Gln-free medium supplemented with OAA or a-KG. Data are
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Figure 5. The GCN2-eIF2a Pathway Activates ATF4 Translation in the Absence of Gln
(A) Diagram depicting pathways involved in selective ATF4 translation. See text for more details.
(B) Western blot analysis of ATF4 and phosphorylated eIF2a (p-eIF2a) in Kelly cells in the presence or absence of Gln. Total eIF2awas used as a loading control.
(C) Immunoblotting of ATF4 and phosphorylated eIF2a (p-eIF2a) in WT MEFs and GCN2- or PERK-deficient (KO) MEFs with or without Gln starvation.
(D) Protein levels of GCN2 and PERK upon the indicated siRNA knockdown in Kelly cells. Error bars represent the SD; *p < 0.005.
(E) Protein levels of ATF4 and phosphorylated eIF2a (p-eIF2a) were detected in Kelly cells transfected with a control or GCN2 or PERK siRNA in the presence or
absence of Gln.
See also Figure S4.
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or ATF4 Stimulation Induces Cell Death In Vitro
and Inhibits Tumorigenesis In Vivo
Because Gln is critical for maintaining TCA-cycle homeostasis
and providing precursors for protein, nucleotide, and lipid
synthesis, we tested whether pharmacological inhibition of Gln
metabolism induces apoptosis. Gln is metabolized to a-KG,
a critical TCA-cycle intermediate, through two deamination
steps: glutaminase converts Gln to glutamate, and then gluta-
mate dehydrogenase (GDH) or transaminases transfer the amino
group to a-keto acids to generate amino acids such as alanine
and aspartate (Figure 6A). Both amino oxyacetate (AOA), a
chemical inhibitor of glutamate-dependent transaminases
(Wise et al., 2008), and epigallocatechin gallate (EGCG), which
inhibits GDH (Li et al., 2007), induced cell death in a dose-
dependent manner in Kelly cells (Figure 6B). Both AOA and
EGCG effectively induced apoptosis at levels comparable to
that resulting from Gln depletion. The effect of AOA and EGCG
was specific to Gln metabolism, as supplementation of OAA or
cell-permeable pyruvate significantly inhibited the toxic effects
of both chemical inhibitors (Figure 6B). To highlight the impor-
tance of enzymes involved in glutaminolysis in maintaining cell
viability, GDH inhibition was also achieved by siRNA knockdown
(Figure S5A). Indeed, GLUD1 (encoding GDH) mRNA degrada-
tion (Figure S5A) triggered dramatic cell death independently
of Gln status, whereas control cells underwent apoptosis only
in the absence of Gln (Figure S5B).
Because Gln starvation resulted in ATF4 accumulation,
PUMA/NOXA/TRB3 induction, and apoptosis, we evaluated
the effect of ATF4 agonists. We chose fenretinide (FRT, also
known as 4-hydroxyphenyl-retinamide), a chemotherapeutic638 Cancer Cell 22, 631–644, November 13, 2012 ª2012 Elsevier Incagent, for the following reasons: (1) preliminary data obtained
from clinical trials demonstrated that FRT is well tolerated in
humans (Villablanca et al., 2006), and (2) FRT induces a signaling
cascade that activates ATF4 and cell death (Corazzari et al.,
2007). Indeed, when incubated with FRT, both Kelly and NLF
cells exhibited increased eIF2a phosphorylation (Figure S5C),
indicating that FRT treatment leads to ER stress in neuroblas-
toma cells, promoting ATF4 translation. In addition, FRT admin-
istration mimics the effect of Gln withdrawal in a number of other
ways, including resistance to Bak inhibition (Figure S5D) and
partial rescue by ATF4 knockdown (Figure 6C), reinforcing the
idea that FRT functions through the ATF4 pathway to induce
cell death in neuroblastoma.
To confirm whether the effects of EGCG and FRT are depen-
dent on N-Myc overexpression, we stably expressed MYCN-
ER in SHEP, a MYCN-nonamplified cell line with undetectable
N-Myc expression (Figure 1A). Induction of MYCN-ER by
4-hydroxytamoxifen in SHEP cells significantly increased the
expression of genes involved in Gln metabolism (Figure 6D)
and sensitized these cells to Gln deprivation (Figure 6E).
More importantly, both EGCG and FRT induced dramatic cell
death in N-Myc-overexpressing SHEP cells (SHEP MYCN-ER)
while causing minimal cell death in control SHEP cells (Fig-
ure 6F), suggesting that both chemicals constitute a synthetic
lethal interaction with MYC transformation in the context of
neuroblastoma.
In addition, administration of either EGCG or FRT to Kelly
cells significantly elevated ATF4, PUMA, and NOXA expression
(Figure 6G), suggesting that either direct inhibition of Gln metab-
olism or activation of upstream signaling achieved a phenotype
similar to that obtained by Gln starvation. When combined with.
Figure 6. Pharmacological Inhibition of Gln Metabolism or ATF4 Hyperactivation Triggers Dramatic Cell Death In Vitro
(A) Diagram showing enzymes involved in glutamate metabolism. See text for details.
(B) Kelly cell death was examined by PI-Annexin V staining upon EGCG or AOA treatment in the presence of Gln. Where indicated, various metabolites were also
supplemented.
(C) Kelly cell death was measured upon fenretinide treatment with or without ATF4 knockdown.
(D) Induction of MYCN-ER and its target genes in SHEP cells. Data are shown as an average of triplicates.
(E) SHEP cell death with or without MYCN-ER induction was quantified by PI-Annexin V staining in the presence or absence of Gln.
(F) SHEP cells with or without MYCN-ER induction were cultured in Gln-replete medium, and their viability was measured upon the indicated drug treatments.
Data are shown as an average of triplicates.
(G) RT-PCR analysis of ATF4, PUMA, and NOXAmRNAs in Kelly cells treated without or with EGCG (50 mM) or fenretinide (5 mM). Data are shown as an average
of triplicates.
(H) Kelly cell death was quantitated by Annexin V-PI staining upon different drug treatments. Where indicated, 25 mM EGCG and/or 3 mM fenretinide was used,
and data are shown as an average of triplicates.
(I) Evaluation of Kelly cell death upon PUMA/NOXA/TRB3 triple knockdown in the presence or absence of fenretinide/EGCG. Experiments were repeated three
times.
All error bars represent SD; *p < 0.01, **p < 0.005. See also Figure S5.
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ure 6H), indicating that their combination could achieve anti-
tumor activity without significant toxicity. Interestingly, other
glutaminolysis enzymes, especially those upregulated in high-
risk neuroblastomas (Figures 1D and S1C), may also become
feasible drug targets, given that they underlie neuroblastoma
Gln addiction (Figures S5E and S5F). Finally, to highlight the
importance of PUMA, NOXA, and TRB3 as the major cell-death
mediators upon drug treatment, we constructed aPUMA/NOXA/
TRB3 stable knockdown variant of the NLF cell line. In contrastCanto control cells, NLF cells with PUMA, NOXA, and TRB3 triple
inhibition exhibited strong resistance to Gln starvation or FRT/
EGCG treatment (Figures 6I, S5G, and S5H).
Together, these in vitro results suggested a functional inter-
play among Gln metabolism, ATF4 activity, and the Myc-driven
oncogenic phenotype of MYCN-amplified neuroblastomas
that can be pharmacologically targeted by FRT and/or EGCG.
However, it remained to be determined whether these signal-
ing events occur in vivo, and whether similar therapeutic
approaches can be applied to other tumors. To investigate thiscer Cell 22, 631–644, November 13, 2012 ª2012 Elsevier Inc. 639
Figure 7. Pharmacological Intervention of
Gln Metabolism or ATF4 Stimulation Signif-
icantly Inhibits MYC-Mediated Xenograft
Tumor Growth
(A) A xenograft tumor growth assay was per-
formed using Kelly cells with EGCG and/or fen-
retinide administration. Representative pictures
of subcutaneous tumors under different treat-
ments are shown.
(B and C) SKNAS cells (B) and P493B lymphoma
cells overexpressing c-Myc (C) were subjected to
the same xenograft experiments as performed
in (A).
(D) Western blot analysis of P493B-inititated
xenograft tumor lysates for the indicated proteins.
(E) ShRNA viruses targeting PUMA, NOXA, and
TRB3 were transduced into P493B cells, and
knockdown efficiencies were evaluated by means
of western blots.
(F) Xenografts of P493B cells with or without
PUMA/NOXA/TRB3 triple knockdown in the
presence or absence of fenretinide/EGCG.
The horizontal lines in (A)–(C) and (F) represent
the average tumor weights for each group. See
also Figure S6.
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ATF4 Regulates MYC-Mediated Cell Deathissue, we established subcutaneous xenografts in nude mice
using Kelly cells. Mice with palpable tumors were randomized
into four groups, each receiving different drug treatments.
Consistent with the in vitro findings, administration of EGCG or
FRT significantly suppressed tumor progression, and combined
treatment resulted in more marked tumor inhibition (Figure 7A).
SKNAS, a MYCN-nonamplified neuroblastoma cell line, was
found to be highly resistant to FRT and EGCG (Figure 7B). We
performed xenograft assays using P493B Burkitt’s lymphoma
cells, which overexpress c-Myc and are addicted to Gln (Figures
S6A and S6B). P493B tumors were also sensitive to FRT and/or
EGCG administration to a similar extent as Kelly xenografts
(Figure 7C). Importantly, P493B tumors treated with FRT/
EGCG exhibited increased expression of ATF4, PUMA, NOXA,
and TRB3 (Figure 7D), indicating that the ATF4-PUMA/NOXA/
TRB3 pathway was activated by these drugs in xenograft640 Cancer Cell 22, 631–644, November 13, 2012 ª2012 Elsevier Inc.lymphomas. In addition, we generated
PUMA/NOXA/TRB3 triple knockdown
P493B cells (Figure 7E), and found that
P493 cells with PUMA/NOXA/TRB3
depletion exhibited substantial resis-
tance to FRT/EGCG treatments in vivo
(Figure 7F), as did PUMA/NOXA/TRB3-
depleted NLF cells (Figure S6C). We
also probed responses to FRT, AOA,
EGCG, or Gln deprivation in A549 lung
cancer cells driven by an oncogenic
KRAS mutation. Interestingly, A549 cells
were resistant to all of these condi-
tions (Figure S6D), and no significant
increases in ATF4, PUMA, NOXA, or
TRB3 protein levels were observed
(Figure S6E). Moreover, FRT/EGCG
treatment failed to inhibit A549-initiatedxenograft tumor growth (Figure S6F), further demonstrating
that ATF4-regulated Gln dependence is tightly linked to MYC
overexpression.
Finally, we tested this approach using the TH-MYCN trans-
genic mouse model, in which spontaneous neuroblastomas
arise in autochthonous tumor sites due to enforced MYCN
expression in neural crest tissues. Homozygous TH-MYCN
mice were treated with AOA or vehicle control at the time
a palpable tumor was documented. As a result, AOA therapy
led to inhibition of tumor growth in comparison with control
mice (Figure 8A), and tumors treated with AOA exhibited induc-
tion of ATF4, PUMA, NOXA, and TRB3 (Figure 8B). The anti-
tumor effects of these drugs (AOA/FRT/EGCG) are not due to
decreased tumor cell proliferation [as evaluated by phosphory-
lated H3 immunoblotting (Figure 7D), Ki-67 staining (Figures 8C
and 8D), or MYC expression (Figures 7D, 8B, and S7A–S7C)],
Figure 8. The Transaminase Inhibitor AOA
Reduces Autochthonous Neuroblastoma
Growth in the TH-MYCN Transgenic Mouse
Model
(A) Tumor-bearing homozygous TH-MYCN mice
were i.p. injected daily with PBS or 10 mg/kg AOA
as described in Experimental Procedures, and
8days later the tumorswere isolated andweighed.
The horizontal lines represent the average tumor
weights for each group. The pictures shown are
of representative neuroblastomas.
(B) Tumors harvested from homozygous TH-
MYCN mice as described in (A) were lysed and
subjected to western blot analysis using the
indicated antibodies.
(C) Ki-67 and c-Caspase 3 staining were per-
formed on paraffin-embedded tumor tissue
sections derived from (A). Representative staining
micrographs are shown. Scale bars represent
100 mm.
(D) Quantification of the results in (C); n = 8, *p <
0.001. Error bars represent SD.
(E) Model depicting the action of Gln in MYC-
overexpressing tumors. See text for additional
details.
See also Figure S7.
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ATF4 Regulates MYC-Mediated Cell Deathbut to significantly increased intratumoral apoptosis as quanti-
fied by cleaved Caspase 3 (c-Caspase 3) levels (Figures 7D,
8C, and 8D). All of these results support the clinical potential
of glutaminolysis inhibitors as cancer therapeutics against
MYC-driven tumors.
DISCUSSION
Cancer cells exhibit increased metabolic autonomy in compar-
ison with normal cells, importing and metabolizing nutrients
required to support their growth and proliferation (Vander Heiden
et al., 2009). The important role played by bioenergetics andCancer Cell 22, 631–644, Nocellular metabolism in the process of
cancer development is receiving re-
newed attention. In order to achieve
rampant proliferation, tumor cells must
duplicate their entire biomass, including
nucleic acids, proteins, and lipids, and
assemble these components in daughter
cells (DeBerardinis et al., 2008). There-
fore, in addition to enhanced energy
generation, tumors alter their metabolism
to generate macromolecules more effi-
ciently. In these processes, Gln plays
an important role. Recently, oncogenic
MYC was shown to reprogram glutami-
nolysis to support biosynthetic activities
through transcriptional and posttran-
scriptional stimulation of genes involved
in Gln metabolism (Gao et al., 2009; Le
et al., 2012; Wise et al., 2008). However,
precisely how Gln deprivation leads to
apoptosis in MYC-transformed cellswas unknown. Using neuroblastoma as a model system, we
were able to identify a pathway that links ATF4 to PUMA/
NOXA/TRB3 activation and cell death upon Gln starvation, and
propose the model shown in Figure 8E. Our results are highly
consistent with the notion that Myc functions as a double-edged
sword in regulating cellular activities, that is, oncogenic Myc
promotes proliferation or apoptosis depending on upstream
signals and enforced dependencies. In Gln-replete conditions,
Myc induces genes (e.g., ASCT2, GLS1, and LAT1) involved in
Gln metabolism to support increased biosynthetic activities.
It should be noted that Myc also regulates gene networks that
activate glucose metabolism, mitochondrial biogenesis, andvember 13, 2012 ª2012 Elsevier Inc. 641
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ATF4 Regulates MYC-Mediated Cell Deathribosome biogenesis (Dang, 2012). In concert, these processes
lead to a robust growth phenotype. When Gln is depleted, cells
initiate a distinct network that includes ATF4 activation. Mecha-
nistically, two pathways mediate ATF4 stimulation upon Gln
deprivation: increased transcription through a currently unknown
mechanism, and enhanced translation via GCN2-eIF2a. ATF4
then activates PUMA and other genes (e.g., NOXA and TRB3)
involved in the execution of cell death, sensitizing tumor cells
to Myc-mediated apoptosis.
Like Myc, ATF4 also plays a dual role in regulating cellular
activities. ATF4’s typical role as a protective factor is well docu-
mented (Ameri and Harris, 2008). Genome-wide profiling in
ATF4 WT and deficient MEFs revealed that ATF4 regulates
amino acid metabolism and resistance to oxidative stress (Ameri
and Harris, 2008). Indeed, Atf4/ fibroblasts are prone to death
in response to stress, including oxidative stress and amino
acid deprivation. Nevertheless, numerous reports have also
described a prodeath role for ATF4 in neurons (Carracedo
et al., 2006; Lange et al., 2008; Ohoka et al., 2005). In contrast
to fibroblasts, ATF4 is a proapoptotic factor in neurons both
in vitro and in vivo (Lange et al., 2008). A subset of ATF4-regu-
lated genes, including TRB3 (Ohoka et al., 2005), promote
neuronal apoptosis, suggesting that context-dependent ATF4
regulation may account for the divergent phenotypes observed.
ATF4 activation also results in tumor cell death under stress
conditions (Ameri and Harris, 2008; Carracedo et al., 2006), sug-
gesting that ATF4 agonists constitute a potential therapeutic
strategy for inhibiting tumor growth. The different metabolic
demands of MYCN-amplified and -nonamplified neuroblas-
tomas may explain the distinct roles for ATF4 in divergent cell
types. Given that ATF4 plays opposing roles (prosurvival versus
prodeath) in different tumors, one must use caution when
considering ATF4 agonists or antagonists as potential therapeu-
tics for cancer treatment.
MYC deregulation occurs frequently in human cancers and
has been estimated to contribute to at least 40% of all human
cancers (Dang, 2012). In multiple models,MYC has been shown
to be continuously required for tumor maintenance (Shachaf
et al., 2004; Soucek et al., 2008), suggesting that direct targeting
of Myc is an effective therapeutic strategy. However, attempts
to chemically disrupt its function have met with limited success,
possibly due to the inherent difficulty of inhibiting transcription
factors with small molecules. Here, we demonstrate and validate
an alternative, pharmacologic approach that exploits the
enforced Gln addiction present in Myc-overexpressing tumor
cells. Previous treatments that involved inducing Gln deficiency
or interfering with its metabolism (e.g., administration of
6-diazo-5-oxo-l-norleucine [DON] and acivicin) showed great
promise in animal models (Ahluwalia et al., 1990) but were
unacceptably toxic in humans and eventually abandoned. In
screens for compounds that suppress Rho GTPase activation
by oncogenic Dbl (for diffuse B cell lymphoma), recent work
identified a tetrahydrobenzo derivative (compound No. 968)
that blocks Rho GTPase-mediated transformation and tumor
growth via mitochondrial glutaminase inhibition (Wang et al.,
2010). Consistent with this finding, administration of BPTES,
another glutaminase inhibitor, significantly decreased xenograft
tumor growth initiated by c-Myc-transformed lymphoma cells
(Le et al., 2012). Nevertheless, the efficacy and toxicity of both642 Cancer Cell 22, 631–644, November 13, 2012 ª2012 Elsevier Inccompound 968 and BPTES for treating human patients remain
largely unknown. Here we show that the combination of FRT
(4-hydroxyphenyl-retinamide) and EGCG is effective for killing
neuroblastoma and lymphoma cells when administered both
in vitro and in vivo. Both drugs are well tolerated in humans
(Khan and Mukhtar, 2008; Villablanca et al., 2006) and may
have clinical utility for human cancers overexpressing the MYC
oncogene. Although FRT alone may not elicit robust antitumor
responses, it could be combined with EGCG as a strategy to
move forward in patient care. Moreover, the development of
drugs targeting Gln metabolism in neuroblastoma should occur




Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS), 2 mM Gln, and 13 penicillin
and streptomycin. To deplete Gln, cells were cultured in Gln-free DMEM sup-
plemented with 10% dialyzed FBS. When indicated, Gln was added back at
a final concentration of 2 mM.
siRNA Knockdown and RNA and Protein Analysis
All assays were performed as described in Qing et al. (2010). Details regarding
the applied siRNAs, primers, and antibodies are provided in Supplemental
Experimental Procedures.
Cell Death Assay
Cells were harvested by combining floating cells in the medium and adherent
cells detached by 0.25% trypsin, and cell pellets were washed once with
cold PBS. Apoptosis was analyzed using the Annexin V-FITC Apoptosis Kit
(BioVision), and data are presented as an average of triplicates.
Luciferase Reporter Assay
Empty pGL3 luciferase vector (0.5 mg) or pGL3 expressing ATF4-RE (or indi-
cated mutants) was transiently cotransfected in triplicate into HEK293T cells
using Fugene 6 (Roche Molecular Biochemicals) with 0.1 mg Renilla luciferase
reporter. When indicated, 0.5 mg pCMV-ATF4 plasmid was included.
Luciferase activities were measured 16–20 hr later with a Dual Luciferase Kit
(Promega). Firefly luciferase activities were normalized to Renilla luciferase
control values and shown as an average of triplicates.
Human Subjects
Primary human neuroblastoma samples were collected and handled at the
Children’s Hospital of Philadelphia with the approval of its institutional review
board committees. Related procedures were performed in accordance with
ethical and legal standards regarding human subjects, and informed consent
was obtained.
Animal Studies
All animal experiments were approved by the Animal Care and Use Committee
at the University of Pennsylvania. For xenograft experiments, female BALB/C
nude mice (Charles River) were injected subcutaneously in both flanks with
three million Kelly, NLF, SKNAS, A549, or P493B cells diluted in 100 ml
DMEMmixedwith an equal volume ofmatrigel (BDBioscience). Once palpable
tumors were established, mice were randomly divided into several groups
receiving different treatments. Fenretinide (1.5 mg/kg) was intravenously in-
jected every 3 days, and EGCG (50 mg/kg) was intraperitoneally (i.p.) injected
daily. Tumor weight was measured at the time of sacrifice. For experiments
using the transgenic mouse model, 30 homozygous TH-MYCN mice bearing
palpable intra-abdominal tumors (ultrasound verified) were randomly divided
into two groups and i.p. injected daily with PBS or 10mg/kg AOA, respectively.
Eight days later, the mice were sacrificed and tumors were isolated and
weighed. To prepare tumor lysates for western blot analysis, the tumors
were snap-frozen in liquid nitrogen, ground with a mortar, and then lysed..
Cancer Cell
ATF4 Regulates MYC-Mediated Cell DeathTo prepare tumor tissue sections for Ki-67 and c-Caspase 3 staining, fresh
tumors were fixed in 10% formalin or 4% formaldehyde, and then dehydrated
with a series of ethanol solutions (75%, 95%, and 100%). Immunohistochem-
ical analyses of Ki-67 and c-Caspase 3 were performed by the Pathology
Core of the Children’s Hospital of Philadelphia. ImageJ software was used
to quantify the staining results.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2012.09.021.
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